Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would ...

Emily J. Kirby, MD and the team at Kalos Medical Spa are now offering ShapeScale, a 3D body scanner that tracks weight loss ...

The Procter & Gamble Company's stagnating revenue growth and premium valuation suggest it's time to explore better value ...

The opioid epidemic, obesity, federal employee suicide and depression rates, and drug prices are on our readers’ minds.

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the ...

Research even suggests it can change users' sense of smell, and other common side effects include diarrhoea, nausea, 'sulphur ...

The average representation of GLP-1 drugs used for weight loss in total annual claims was 10.5% for 2025, an increase over ...

Whichever way the tariff winds blow (and I've no special knowledge of that), Novo Nordisk stock remains arguably the cheapest ...

In 2024, 4% of U.S. adults were prescribed a GLP-1 therapy — a 363.7% increase from 0.9% in 2019, according to a Fair Health analysis of more than 51 billion commercial claim records.  Fair Health ...

As Australia faces a turning point in obesity management, researchers from Monash University have contributed new insights ...

A federal deadline ending the sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on.

The supply of GLP-1 drugs like Ozempic has been increasing, but they’re still expensive for most patients. Here are answers ...